Abstract
Chemotherapy is standard therapy for metastatic disease. However, aggressive local therapies may improve outcomes for selected patients (pts) with oligometastatic disease. SBRT in early stage non-small cell lung cancer (NSCLC) has high rates of local control (LC), but little data exist assessing SBRT to treat lung metastases. We assess safety and efficacy of SBRT in pts with 1-5 pulmonary metastases and limited extrathoracic disease, and we compare outcomes by disease. We hypothesized SBRT to lung metastases could achieve high LC across diverse primary tumor types, and overall survival (OS) would vary by disease site of origin and time from stage IV diagnosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
